| General Information of Drug Metabolite (DM) (ID: DM018231) |
| DM Name |
Mono-hydroxyralfinamide
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Unclear - Unclear |
Ralfinamide
|
[1] |
|
|
|
|
|
|
|
| DME(s) Metabolizing This DM |
| DME Name |
DME ID |
Product |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Unclear - Unclear |
Ralfinamide
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Ralfinamide |
DR5016
|
Phase 3 |
Neuropathic pain |
|
|
| References |
| 1 |
Disposition and metabolism of ralfinamide, a novel Na-channel blocker, in healthy male volunteers
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
